J Korean Med Sci.  2015 May;30(5):552-558. 10.3346/jkms.2015.30.5.552.

Infliximab Partially Alleviates the Bite Force Reduction in a Mouse Model of Temporomandibular Joint Pain

• Kim SH
• Son CN
• Lee HJ
• Cho HC
• Jung SW
• Hur JA
• Baek WK
• Jung HR
• Hong JH

• KMID: 2155467
• DOI: http://doi.org/10.3346/jkms.2015.30.5.552

Abstract

Temporomandibular joint (TMJ) disorder is clinically important because of its prevalence, chronicity, and therapy-refractoriness of the pain. In this study, we investigated the effect of infliximab in a mouse model of TMJ pain using a specially-engineered transducer for evaluating the changes in bite force (BF). The mice were randomly divided into three groups (7 mice per group): the control group, the complete Freund's adjuvant (CFA) group, and the infliximab group. BF was measured at day 0 (baseline BF). After measuring the baseline BF, CFA or incomplete Freund's adjuvant was injected into both TMJs and then the changes in BF were measured at days 1, 3, 5, 7, 9, and 13 after the TMJ injection. For measuring the BF, we used a custom-built BF transducer. Control, CFA, and infliximab groups showed similar baseline BF at day 0. From day 1, a significant reduction in BF was observed in the CFA group, and this reduction in BF was statistically significant compared to that in the control group (P < 0.05). This reduction in BF was maintained until day 7, and BF started to recover gradually from day 9. In the infliximab group also, the reduction in BF was observed on day 1, and this reduction was maintained until day 7. However, the degree of reduction in BF was less remarkable compared to that in the CFA group. The reduction in BF caused by injection of CFA into the TMJ could be partially alleviated by the injection of anti-tumor necrosis factor alpha, infliximab.

Keyword

Bite Force; Infliximab; Temporomandibular Joint Pain

MeSH Terms

Animals
Antirheumatic Agents/*therapeutic use
*Bite Force
Disease Models, Animal
Freund's Adjuvant/toxicity
Infliximab/*therapeutic use
Male
Mice
Mice, Inbred ICR
Temporomandibular Joint/pathology
Temporomandibular Joint Disorders/chemically induced/*drug therapy/pathology
Time Factors
Antirheumatic Agents
Freund's Adjuvant
Infliximab

Figure

• 

  Fig. 1 Photograph showing the transducer (A) and bridge module (B). Arrow indicates the strain gauges.

• 

  Fig. 2 Bite force voltage output wave through the computer monitor (A, B).

• 

  Fig. 3 Changes in bite force from day 0 to day 13 in the control, complete Freund's adjuvant (CFA), and infliximab groups. *Statistically significant compared to that in the CFA group.

• 

  Fig. 4 Temeporomandibular joint of control (A), infliximab group (B), and CFA group (C) (H&E, ×40). The synovial membrane of control group (D) is smooth and lined by 1-2 synovial cells (H&E, ×400). In infliximab group (E), synovial membrane is lined by 2-3 cells (arrowhead) and shows moderate degree of chronic inflammation (H&E, ×400). The CFA group (F) shows severe inflammation and marked synovial hyperplasia which shows irregularly piled synovial cells (arrows) (H&E, ×400).

Reference

1. Turman JE Jr. The development of mastication in rodents: from neurons to behaviors. Arch Oral Biol. 2007; 52:313–316.

2. Yamada Y, Yamamura K, Inoue M. Coordination of cranial motoneurons during mastication. Respir Physiol Neurobiol. 2005; 147:177–189.

3. Westberg KG, Kolta A. The trigeminal circuits responsible for chewing. Int Rev Neurobiol. 2011; 97:77–98.

4. Cadden SW, Orchardson R. Mastication and swallowing: 2. control. Dent Update. 2009; 36:390–392. 394–396. 398

5. Marquezin MC, Kobayashi FY, Montes AB, Gavião MB, Castelo PM. Assessment of masticatory performance, bite force, orthodontic treatment need and orofacial dysfunction in children and adolescents. Arch Oral Biol. 2013; 58:286–292.

6. Kogawa EM, Calderon PS, Lauris JR, Araujo CR, Conti PC. Evaluation of maximal bite force in temporomandibular disorders patients. J Oral Rehabil. 2006; 33:559–565.

7. Wang XD, Kou XX, He DQ, Zeng MM, Meng Z, Bi RY, Liu Y, Zhang JN, Gan YH, Zhou YH. Progression of cartilage degradation, bone resorption and pain in rat temporomandibular joint osteoarthritis induced by injection of iodoacetate. PLoS One. 2012; 7:e45036.

8. Lee JK, Cho YS, Song SI. Relationship of synovial tumor necrosis factor alpha and interleukin 6 to temporomandibular disorder. J Oral Maxillofac Surg. 2010; 68:1064–1068.

9. Nicoll SB, Hee CK, Davis MB, Winkelstein BA. A rat model of temporomandibular joint pain with histopathologic modifications. J Orofac Pain. 2010; 24:298–304.

10. Wu YW, Bi YP, Kou XX, Xu W, Ma LQ, Wang KW, Gan YH, Ma XC. 17-Beta-estradiol enhanced allodynia of inflammatory temporomandibular joint through upregulation of hippocampal TRPV1 in ovariectomized rats. J Neurosci. 2010; 30:8710–8719.

11. Chen Y, Williams SH, McNulty AL, Hong JH, Lee SH, Rothfusz NE, Parekh PK, Moore C, Gereau RW 4th, Taylor AB, et al. Temporomandibular joint pain: a critical role for Trpv4 in the trigeminal ganglion. Pain. 2013; 154:1295–1304.

12. Boettger MK, Hensellek S, Richter F, Gajda M, Stöckigt R, von Banchet GS, Bräuer R, Schaible HG. Antinociceptive effects of tumor necrosis factor alpha neutralization in a rat model of antigen-induced arthritis: evidence of a neuronal target. Arthritis Rheum. 2008; 58:2368–2378.

13. Gruber-Schoffnegger D, Drdla-Schutting R, Hönigsperger C, Wunderbaldinger G, Gassner M, Sandkühler J. Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord lamina I by TNF-α and IL-1β is mediated by glial cells. J Neurosci. 2013; 33:6540–6551.

14. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol. 2001; 19:163–196.

15. Sanmarti R, Ruiz-Esquide V, Hernández MV. Rheumatoid arthritis: a clinical overview of new diagnostic and treatment approaches. Curr Top Med Chem. 2013; 13:698–704.

16. Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006; 10:iii–iiv. xi–xiii. 1–229.

17. Williams SH, Peiffer E, Ford S. Gape and bite force in the rodents Onychomys leucogaster and Peromyscus maniculatus: does jaw-muscle anatomy predict performance? J Morphol. 2009; 270:1338–1347.

18. Reiter S, Goldsmith C, Emodi-Perlman A, Friedman-Rubin P, Winocur E. Masticatory muscle disorders diagnostic criteria: the American Academy of Orofacial Pain versus the research diagnostic criteria/temporomandibular disorders (RDC/TMD). J Oral Rehabil. 2012; 39:941–947.

19. Winocur E, Gavish A, Finkelshtein T, Halachmi M, Gazit E. Oral habits among adolescent girls and their association with symptoms of temporomandibular disorders. J Oral Rehabil. 2001; 28:624–629.

20. Gavish A, Winocur E, Menashe S, Halachmi M, Eli I, Gazit E. Experimental chewing in myofascial pain patients. J Orofac Pain. 2002; 16:22–28.

21. Dolan JC, Lam DK, Achdjian SH, Schmidt BL. The dolognawmeter: a novel instrument and assay to quantify nociception in rodent models of orofacial pain. J Neurosci Methods. 2010; 187:207–215.

22. Kubota E, Imamura H, Kubota T, Shibata T, Murakami K. Interleukin 1 beta and stromelysin (MMP3) activity of synovial fluid as possible markers of osteoarthritis in the temporomandibular joint. J Oral Maxillofac Surg. 1997; 55:20–27. discussion 7-8.

23. Fu K, Ma X, Zhang Z, Pang X, Chen W. Interleukin-6 in synovial fluid and HLA-DR expression in synovium from patients with temporomandibular disorders. J Orofac Pain. 1995; 9:131–137.

24. Hensellek S, Brell P, Schaible HG, Bräuer R, Segond von Banchet G. The cytokine TNFalpha increases the proportion of DRG neurones expressing the TRPV1 receptor via the TNFR1 receptor and ERK activation. Mol Cell Neurosci. 2007; 36:381–391.

25. Schäfers M, Geis C, Brors D, Yaksh TL, Sommer C. Anterograde transport of tumor necrosis factor-alpha in the intact and injured rat sciatic nerve. J Neurosci. 2002; 22:536–545.

26. Schäfers M, Lee DH, Brors D, Yaksh TL, Sorkin LS. Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci. 2003; 23:3028–3038.

27. Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain. 2006; 123:306–321.

28. Chen BL, Li YQ, Xie DH, He QL, Yang XX. Blocking TNF-α with infliximab alleviates ovariectomy induced mechanical and thermal hyperalgesia in rats. Neurol Sci. 2012; 33:527–533.

29. Ohtani T, Habu M, Khanal A, Yoshioka I, Matsukawa A, Tominaga K. Local effects of intra-articular injection of anti-rabbit tumor necrosis factor alpha monoclonal antibody in antigen-induced arthritis of the rabbit temporomandibular joint. J Oral Pathol Med. 2012; 41:96–105.